309 related articles for article (PubMed ID: 37957717)
21. Adverse Event Profiles of Anti-CTLA-4 and Anti-PD-1 Monoclonal Antibodies Alone or in Combination: Analysis of Spontaneous Reports Submitted to FAERS.
Ji HH; Tang XW; Dong Z; Song L; Jia YT
Clin Drug Investig; 2019 Mar; 39(3):319-330. PubMed ID: 30674039
[TBL] [Abstract][Full Text] [Related]
22. Signal mining and analysis for central nervous system adverse events due to taking oxycodone based on FAERS database.
Wu X; Zhang L; Huang H; Huang L; Lu X; Wang Z; Xiao J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Mar; 48(3):422-434. PubMed ID: 37164926
[TBL] [Abstract][Full Text] [Related]
23. A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for venetoclax.
Yang Y; Shu Y; Chen G; Yin Y; Li F; Li J
PLoS One; 2022; 17(12):e0278725. PubMed ID: 36477747
[TBL] [Abstract][Full Text] [Related]
24. Disproportionality analysis of quinolone safety in children using data from the FDA adverse event reporting system (FAERS).
Kong W; Mao W; Zhang L; Wu Y
Front Pediatr; 2022; 10():1069504. PubMed ID: 36714649
[TBL] [Abstract][Full Text] [Related]
25. Pharmacovigilance Study of Infigratinib: A Safety Analysis of the FDA Adverse Event Reporting System.
Zhao D; Long X; Zhou J; Wang J
Drugs R D; 2023 Dec; 23(4):403-409. PubMed ID: 37700091
[TBL] [Abstract][Full Text] [Related]
26. A real-world disproportionality analysis of Rucaparib: Post-marketing Pharmacovigilance Data.
Zhang Q; Ding Y; Shu Y; Chen J
BMC Cancer; 2023 Aug; 23(1):745. PubMed ID: 37568126
[TBL] [Abstract][Full Text] [Related]
27. Cardiovascular toxicity associated with angiogenesis inhibitors: A comprehensive pharmacovigilance analysis based on the FDA Adverse Event Reporting System database from 2014 to 2021.
Wang Y; Cui C; Ren X; Dong X; Cui W
Front Cardiovasc Med; 2022; 9():988013. PubMed ID: 36312283
[TBL] [Abstract][Full Text] [Related]
28. A pharmacovigilance analysis of FDA adverse event reporting system events for romosozumab.
Chen Z; Li M; Li S; Li Y; Wu J; Qiu K; Yu X; Huang L; Chen G
Expert Opin Drug Saf; 2023 Apr; 22(4):339-342. PubMed ID: 36178002
[TBL] [Abstract][Full Text] [Related]
29. Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database.
Liu W; Du Q; Guo Z; Ye X; Liu J
Front Pharmacol; 2023; 14():1283247. PubMed ID: 38027003
[No Abstract] [Full Text] [Related]
30. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
[TBL] [Abstract][Full Text] [Related]
31. A real-world disproportionality analysis of mesalazine data mining of the public version of FDA adverse event reporting system.
Liu M; Gu L; Zhang Y; Zhou H; Wang Y; Xu ZX
Front Pharmacol; 2024; 15():1290975. PubMed ID: 38357304
[No Abstract] [Full Text] [Related]
32. Cardiac toxicity of brentuximab vedotin: a real-word disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database.
Ke C; Chen M; Huang Y; Chen Y; Lin C; Huang P
Naunyn Schmiedebergs Arch Pharmacol; 2024 Jan; ():. PubMed ID: 38270617
[TBL] [Abstract][Full Text] [Related]
33. Cardiac adverse events associated with quetiapine: Disproportionality analysis of FDA adverse event reporting system.
Shu Y; Ding Y; Liu L; Zhang Q
CNS Neurosci Ther; 2023 Sep; 29(9):2705-2716. PubMed ID: 37032639
[TBL] [Abstract][Full Text] [Related]
34. Drug-induced interstitial lung disease: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System from 2004 to 2021.
Jiang T; Su H; Xu J; Li C; Zhang N; Li Y; Wu Y; Ni R; Ming Y; Li Z; Li L; Liu Y
Ther Adv Drug Saf; 2024; 15():20420986231224227. PubMed ID: 38293566
[TBL] [Abstract][Full Text] [Related]
35. Comparison of Online Patient Reviews and National Pharmacovigilance Data for Tramadol-Related Adverse Events: Comparative Observational Study.
Park S; Choi SH; Song YK; Kwon JW
JMIR Public Health Surveill; 2022 Jan; 8(1):e33311. PubMed ID: 34982723
[TBL] [Abstract][Full Text] [Related]
36. Metformin adverse event profile: a pharmacovigilance study based on the FDA Adverse Event Reporting System (FAERS) from 2004 to 2022.
Du Y; Zhu J; Guo Z; Wang Z; Wang Y; Hu M; Zhang L; Yang Y; Wang J; Huang Y; Huang P; Chen M; Chen B; Yang C
Expert Rev Clin Pharmacol; 2024; 17(2):189-201. PubMed ID: 38269492
[TBL] [Abstract][Full Text] [Related]
37. Adverse Event Profile Differences between Trastuzumab Emtansine and Trastuzumab Deruxtecan: A Real-world, Pharmacovigilance Study.
Liu F; Yin G; Xue S; Rehman FU; Liao D; Pan Y
J Cancer; 2023; 14(17):3275-3284. PubMed ID: 37928419
[No Abstract] [Full Text] [Related]
38. Data mining and analysis for emicizumab adverse event signals based on the Food and Drug Administration Adverse Event Reporting System database.
Wei L; Tian Y; Chen X; Guo X; Chen C; Zheng Y; Xu J; Ye X
Int J Clin Pharm; 2023 Jun; 45(3):622-629. PubMed ID: 36848023
[TBL] [Abstract][Full Text] [Related]
39. Disproportionality Analysis of Abemaciclib in the FDA Adverse Event Reporting System: A Real-World Post-Marketing Pharmacovigilance Assessment.
Shu Y; Wang L; Ding Y; Zhang Q
Drug Saf; 2023 Sep; 46(9):881-895. PubMed ID: 37418089
[TBL] [Abstract][Full Text] [Related]
40. Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system.
Shu Y; He X; Wu P; Liu Y; Ding Y; Zhang Q
Front Public Health; 2022; 10():996179. PubMed ID: 36339230
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
